Haisco Pharmaceutical plans A-share issuance for R&D

Haisco Pharmaceutical Group Co., Ltd. announced a non-public issuance of A-shares to specific investors in 2025, aiming to raise up to 1,365.26 million yuan. The funds will be primarily allocated to new drug R&D projects (965.26 million yuan) and supplementary working capital (400 million yuan). This issuance seeks to strengthen the company's R&D capabilities and accelerate the commercialization of its innovative drug pipeline, including late-stage clinical trials for HSK31679, HSK31858, HSK39297, HSK21542, and HL231.

Haisco Pharmaceutical's focus on R&D is evident from its investments, with R&D expenditures of 496.55 million yuan in the first six months of 2025 and 1,000.94 million yuan in 2024. This represents 24.82% and 26.90% of operating income, respectively. The issuance, comprising up to 70 million shares, is expected to maintain Wang Junmin's controlling stake, with his and his concerted parties' shareholding projected to decrease to 37.75%.